Antibody Drug Conjugate Market Size, Competitors & Forecast

The global antibody drug conjugate market is estimated to grow from USD 7.72 billion in the current year to USD 23.3 billion by 2035, at a CAGR of 9.63% during the forecast period, till 2035.

Antibody Drug Conjugate Market: Growth and Trends

Over the years, various technical developments, such as enhanced pharmacokinetic and pharmacodynamic properties and antibody engineering have paved the way for antibody drug conjugates to be considered as a viable therapeutic modality for the treatment of solid tumors and hematological malignancies. Till date, over 280 antibody drug conjugates have been either approved or being investigated in clinical studies, whereas more than 250 candidates are in the early stages of development. Examples of the USFDA approved drugs include Zynlonta, Akalux, Aidixi.

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side effects. Till date, several clinical trials have shown the therapeutic superiority (over conventional cancer treatment options) and efficacy of antibody-drug conjugates. Therefore, the rising population of various oncological disorders is one of the key drivers for the antibody drug conjugate market. Driven by the availability of innovative technology platforms, lucrative funding opportunities and encouraging clinical trial results, the antibody drug conjugates market is poised to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.

Antibody Drug Conjugate Market: Key Insights

The report delves into the current state of the antibody drug conjugate market and identifies potential growth opportunities within the industry. Some key findings from the report include:

The landscape of ADCs has steadily evolved over the past decade; more than 530 ADC therapy programs are being evaluated by over 140 drug developers, worldwide.

Currently, 47% of the ADCs are in discovery / preclinical stages of development; of these, close to 160 ADCs utilize auristatin and maytansinoid payloads.
In order to gain a competitive edge, ADC developers are actively exploring novel targets for the treatment of a wide array of indications.
Since 2010, 560+ clinical trials have been registered to evaluate the safety and efficacy of various ADCs; majority of these studies have been conducted across various sites in the US.
Developers have already evaluated more than 190 ADCs in combination with other therapeutic modalities for the treatment of various oncological disorders.

The growing interest in this field is evident from the rise in partnership activity over the years; in fact, the maximum partnerships, till date, were inked recently.
Considering the enormous opportunities associated with ADCs for the treatment of cancer, investors have readily extended funds, worth nearly USD 30 billion, in the last decade.
Several researchers from renowned universities, currently involved in evaluating efficacy and safety of ADCs, have emerged as prominent KOLs.
Over the years, the intellectual capital related to the therapeutic applications of ADCs has grown at a commendable pace; more than 3,330 patents have been filed by both industry and non-industry players.
A number of grants, worth over USD 135 million, have been awarded for research activity related to ADCs; nearly 90% of these grants extend a support period of up to 10 years.
Stakeholders are exploring diverse commercialization strategies across different stages of a drug’s launch cycle; for drugs nearing patent expiry, these developers are expected to adopt lifecycle management strategies.
Presently, around 35 players, across the globe, claim to have the required capabilities to offer contract manufacturing / conjugation services for ADCs; of these, over 10 players claim to be one-stop-shops.
With a promising developmental pipeline, the global market is anticipated to witness an annualized growth of nearly 10% over the next decade.

Antibody Drug Conjugate Market Overview

No. of ADCs Approved / Under Development across Clinical and Preclinical Stages: 530+
Amount Invested in this Domain to Date: USD ~30 Billion
Current Market Size: USD 7.72 Billion
Market Size in 2035: USD 23.3 Billion
CAGR 9.63%

Target Disease Indication:

Breast Cancer
B-cell Lymphoma
Lung Cancer
Multiple Myeloma
Acute Lymphoblastic Leukemia
Gastric Cancer
Renal Cancer
Cervical Cancer
Other Target Disease Indications

Therapeutic Area:

Hematological Cancer
Solid Tumor

ANTIBODY DRUG CONJUGATE MARKET: KEY SEGMENTS

Breast Cancer is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period

Based on the target disease indication, the market is segmented into breast cancer, b-cell lymphoma, lung cancer, multiple myeloma, acute lymphoblastic leukemia, gastric cancer, renal cancer, cervical cancer and other target disease indications. Currently, a number of antibody drug conjugates have been approved for the treatment of breast cancer patients. This segment is expected to capture the largest share as more drug candidates receive approvals in the future.

Currently, Solid Tumor Holds Maximum Share within the Antibody Drug Conjugate Market

Based on the therapeutic area, the market is segmented into hematological cancer and solid tumor. It is worth highlighting that antibody drug conjugate market for solid tumor is likely to grow at a relatively higher CAGR, during the forecast period.

Maleimidocaproyl is the Fastest Growing Segment in the Antibody Conjugate Market During the Forecast Period

Based on the type of linker, the market is segmented into valine-citrulline, succinimidyl-4-(n-maleimidomethyl) cyclohexane-1-carboxylate, tetrapeptide-based linker, maleimidocaproyl, valine-alanine, hydrazone (4-(4-acetylphenoxy) butanoic acid (acbut) and other linkers. It is worth highlighting that the current antibody drug conjugate market is dominated by valine-citrulline linkers.

Monomethyl auristatin E (MMAE) Payload is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period

Based on the type of payload, the market is segmented into Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and other Payloads. The current market is expected to be driven by MMAE payload used in antibody drug conjugates, followed by DM1; a similar trend is anticipated in the long term.

Currently, HER-2 (ERBB2) Target Antigen Holds the Maximum Share within the Antibody Drug Conjugate Market

Based on the target antigen, the market is segmented into HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, tissue factor, CD30, CEACAM5, Nectin 4 and others.

The market is expected to be driven by HER-2 (ERBB2) antigen, CD79b target antigen and TROP-2 antigen in mid-long term. It is worth highlighting that the antibody drug conjugate market for tissue factor is likely to grow at a relatively higher CAGR during the forecast period.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe and Asia-Pacific. Majority share is expected to be captured by drug developers based in North America and Europe. It is worth highlighting that over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Key Players in the Antibody Drug Conjugates Market

ADC Therapeutics
Astellas Pharma
AstraZeneca
Byondis
Daiichi Sankyo
Genentech
Gilead Sciences
ImmunoGen
Pfizer
RemeGen

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Founder and Chief Executive Officer, Oxford Biotherapeutics
Founder and Chief Operating Officer, Angiex
Co-Founder and Chief Executive Officer, Syndivia
President and Chief Executive Officer, BSP Pharmaceuticals
Former Chief Executive Officer, PolyTherics (an Abzena company)
Founder and Chief Executive Officer, CureMeta
Chief Business Officer and Head of Strategy, CytomX Therapeutics
Former Chief Business Officer, NBE-Therapeutics
Chief Commercial Officer, Cerbios-Pharma
Senior Vice President and Chief Scientific Officer, Eisai
Chief Business Officer, AbTis
Former Vice President and Head of Chemistry, AmbrX
Vice President, Business Development, Synaffix
Former Director, Pierre Fabre
Former Group Product Manager, Catalent Pharma Solutions
Former Head of Bioconjugates Commercial Development, Lonza
Former Site Head, Piramal Healthcare
General Manager, Business Development, CDMO Business, Ajinomoto Bio-Pharma Services
Professor, Cardiff University

Antibody Drug Conjugate Market: Research Coverage

The report features an in-depth analysis of the antibody drug conjugate market, focusing on key market segments, including target disease indication, therapeutic area, linker, payload, target antigens and key geographical regions.
A comprehensive evaluation of close to 400 antibody drug conjugates / ADC therapeutics that have been either approved or being evaluated in different stages of development, considering various parameters, such as status of development (Approved, Phase III, Phase II, Phase I and Discovery / Preclinical), target disease indication (breast cancer, lung cancer, gastric cancer, ovarian cancer, non-Hodgkin’s lymphoma, hepatic cancer, b-cell lymphoma, acute myeloid leukemia, brain cancer and renal cancer), therapeutic area (solid tumors, hematological cancers, autoimmune disorders / inflammatory disorders and others), line of treatment (1st line, ≥1st line, 2nd line, ≥2nd line, 3rd line, ≥3rd line, ≤4th line, Last line and others), dosing frequency (q3 weeks, q2 weeks, q1 weeks, q4 weeks, once and q6 weeks), type of therapy (combination therapy and monotherapy), target antigen (HER-2 (ERBB2), Trop-2, EGFR, FOLR1 (folate receptor alpha), CD30, B7-H3 (CD276), Nectin 4 and c-MET), antibody isotype (IgG1, IgG2 and IgG4), payload / cytotoxin / warhead (monomethyl auristatin E (MMAE), DM4, DM1, SG3199, SN-38 / irinotecan, duocarmycin and monomethyl auristatin F (MMAF)), type of payload (auristatin, Maytansinoid, camptothecin, exatecan derivative topoisomerase I inhibitor, pyrrolobenzodiazepine dimer, topoisomerase I inhibitor (unspecified), DNA topoisomerase I inhibitor, Seco-DUBA, calicheamicin (ozogamicin), glucocorticoid and pyrrolobenzodiazepine (PBD)), linkers (valine-citrulline, peptide linker, tetrapeptide-based linker, N-succinimidyl 4-(2-pyridyldithio) -butanoate (SPDB), valine-alanine, succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate and maleimide linker) and type of linkers (cleavable and non-cleavable). In addition, it includes information on various antibody drug conjugate developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of therapies).
A comprehensive competitive analysis of biological targets, examining factors, such as number of antibody drug conjugates being developed against them, number of unique target disease indications and number of companies developing antibody-drug conjugates for the target. In addition, it includes a six-dimensional spider-web analysis, featuring the most popular biological targets based on a number of relevant parameters, including number of publications, number of grants received to support research on a particular target, number of companies involved in drug development based on a singular target, highest phase of development for the singular target, number of therapies and number of indications.
In-depth profiles of key industry players in antibody drug conjugate market, focusing on company overviews, financial information (if available), product portfolio, recent developments, and an informed future outlook.
Detailed profiles of marketed ADC therapeutics, focusing on overview of the therapy, its mechanism of action, target antigen, linker, payload, type of therapy and details related to sales generated (wherever available).
Examination of completed, ongoing, and planned clinical studies of various drug conjugates based on several parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor / collaborator, target population, study design, most active industry players, and non-industry players (in terms of number of trials) and key geographical regions.
An in-depth examination that emphasizes the key opinion leaders (KOLs) within this field includes an evaluation of various principal investigators overseeing clinical trials associated with antibody drug conjugates, based on several relevant parameters, such as type of KOL, qualification(s), type of organization, affiliated organization, geographical location of KOLs and target disease indications. In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
An assessment of various therapeutics that are being evaluated in combination with antibody-drug conjugates. The study also presents the likely evolution of these therapeutics across different indications.
An analysis of partnerships established in this sector, since 2014, covering product licensing agreements, technology licensing agreements, research and development agreements, clinical trial agreements, mergers / acquisitions, product development agreements, technology utilization agreements, product development and commercialization agreements, manufacturing agreements, technology integration agreements and others), purpose of partnership (research and development, product development and commercialization, product development, clinical evaluation, portfolio enhancement, product development and manufacturing, manufacturing, research and others.
A detailed evaluation of the investments made in the ADC domain, encompassing seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings based on several parameters, such as number of funding instances, amount invested, type of funding, leading companies and investors, and geographical analysis.
Detailed analysis of various patents filed / granted related to antibody drug conjugates based on type of patent, patent publication year, patent application year, geographical location, type of players, assigned CPC symbol, type of organization, and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
A comprehensive evaluation of various grants that have been awarded to research institutes engaged in conducting research related to antibody drug conjugates, since 2016, based on various important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, popular NIH departments (based on number of grants awarded), prominent program officers, leading recipient organizations and key regions.
A detailed analysis of the commercialization strategies employed by different drug developers for their respective products, prior to launch, during / post launch. It also includes a proprietary framework to outline the essential steps and guidelines that companies can follow while developing their marketing strategies.
An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely Adcetris, Besponsa, Enhertu, Kadcyla, Mylotarg, Polivy, and Trodelvy.
Assessment of the success protocol model for the recently approved ADC therapeutics, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.
An overview of various conjugation and linker technologies along with the types that are presently being employed in the designing and development of antibody drug conjugates. In addition, it presents a list of the conjugation and linker technologies that are presently being employed in the designing and development of antibody drug conjugates.
An overview of research aimed at enhancing the analysis of non-clinical data to support first-in-human (FIH) dose selection for antibody drug conjugates. It also examines the various methods employed to estimate FIH doses. Additionally, it highlights potential FIH starting doses and the estimated dose escalations necessary to achieve the maximum tolerated dose (MTD) in humans.
A comprehensive discussion on the various factors that are likely to influence the pricing of antibody drug conjugate products. This includes an exploration of different models and approaches that pharmaceutical companies may consider while determining the prices of their lead therapy candidates that are likely to be marketed in the near future.
A case study on manufacturing of antibody drug conjugates, highlighting the key challenges, and a list of contract service providers that are involved in the ADC market.
A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving antibody-drug conjugates, providing information on the geographical location of key diagnostic developers, affiliated disease biomarkers, assay techniques involved, target indications, the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidates for which a particular test was developed.
A SWOT analysis, focusing on key drivers and challenges that are likely to impact the industry’s evolution. Further, it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What are the factors that are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. ADC Contract Manufacturers: Market Overview
1.2. Market Share Insights
1.3. Market Segmentation Overview
1.4. Key Market Insights
1.5. Report Coverage
1.6. Key Questions Answered
1.7. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Key Components of ADCs
5.2.1. Antibody
5.2.2. Cytotoxin (Payloads)
5.2.3. Linker
5.3. ADC Manufacturing
5.3.1. Key Steps
5.3.2. Technical Challenges
5.3.3. Need for Outsourcing
5.4. Challenges Associated with Supply Chain and Method Transfer
5.4.1. Growing Demand for One-Stop Shops and Integrated Service Providers
5.5. Selecting a CMO Partner
5.6. Future Perspective

6. ADC CONTRACT MANUFACTURERS: MARKET LANDSCAPE

6.1. Chapter Overview
6.2. ADC Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of ADC Manufacturing Service Offered
6.2.5. Analysis by Type of Additional Service Offered
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Location of Manufacturing Facilities

7. COMPANY PROFILES

7.1. Chapter Overview
7.2. MabPlex
7.2.1. Company Overview
7.2.2. ADC Related Services
7.2.3. Manufacturing Facilities
7.2.4. Recent Developments and Future Outlook
7.3. Lonza
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. ADC Related Services
7.3.4. Manufacturing Facilities
7.3.5. Recent Developments and Future Outlook
7.4. Abzena
7.4.1. Company Overview
7.4.2. ADC Related Services
7.4.3. Manufacturing Facilities
7.4.4. Recent Developments and Future Outlook
7.5. GBI
7.5.1. Company Overview
7.5.2. ADC Related Services
7.5.3. Manufacturing Facilities
7.5.4. Recent Developments and Future Outlook

7.6. CARBOGEN AMCIS
7.6.1. Company Overview
7.6.2. ADC Related Services
7.6.3. Manufacturing Facilities
7.6.4. Recent Developments and Future Outlook
7.7. Millipore Sigma
7.7.1. Company Overview
7.7.2. ADC Related Offerings
7.7.3. Manufacturing Facilities
7.7.4. Recent Developments and Future Outlook
7.8. WuXi Biologics
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. ADC Related Services
7.8.4. Manufacturing Facilities
7.8.5. Recent Developments and Future Outlook
7.9. Catalent Pharma Solutions
7.9.1. Company Overview
7.9.2. Financial Information
7.9.3. ADC Related Services
7.9.4. Manufacturing Facilities
7.9.5. Recent Developments and Future Outlook
7.10. Cerbios-Pharma
7.10.1. Company Overview
7.10.2. ADC Related Services
7.10.3. Manufacturing Facilities
7.10.4. Recent Developments and Future Outlook
7.11. Formosa Laboratories
7.11.1. Company Overview
7.11.2. ADC Related Services
7.11.3. Manufacturing Facilities
7.11.4. Recent Developments and Future Outlook
7.12. Sterling Pharma Solutions
7.12.1. Company Overview
7.12.2. ADC Related Services
7.12.3. Manufacturing Facilities
7.12.4. Recent Developments and Future Outlook
7.13. Piramal Pharma Solutions
7.13.1. Company Overview
7.13.2. ADC Related Services
7.13.3. Manufacturing Facilities
7.13.4. Recent Developments and Future Outlook
7.14. AbbVie Contract Manufacturing
7.14.1. Company Overview
7.14.2. ADC Related Services
7.14.3. Manufacturing Facilities
7.14.4. Recent Developments and Future Outlook

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. ADC Contract Manufacturers: Company Competitiveness Analysis
8.4.1. ADC Contract Manufacturers based in North America (Peer Group I)
8.4.2. ADC Contract Manufacturers based in Europe (Peer Group II)
8.4.3. ADC Contract Manufacturers based in Asia-Pacific (Peer Group III)
8.5. Capability Benchmarking of Top ADC Contract Manufacturers

9. ADC CONTRACT MANUFACTURERS: RECENT EXPANSIONS

9.1. Chapter Overview
9.2. ADC Contract Manufacturers: Recent Expansions
9.2.1. Analysis by Year of Expansion
9.2.2. Analysis by Type of Expansion
9.2.3. Analysis by Purpose of Expansion
9.2.4. Analysis by Scale of Operation
9.2.5. Analysis by Location of Expanded Facility
9.2.6. Most Active Players: Analysis by Number of Expansions

10. ADC CONTRACT MANUFACTURERS: PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview
10.2. Partnership Models
10.3. ADC Contract Manufacturers: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Purpose of Partnership
10.3.4. Analysis by Scale of Operation
10.3.5. Most Active Players: Analysis by Number of Partnerships
10.3.6. Analysis by Geography
10.3.6.1. Intercontinental and Intracontinental Agreements
10.3.6.2. Local and International Agreements

11. MAKE VERSUS BUY DECISION MAKING

11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.2.1. Scenario 1
11.2.2. Scenario 2
11.2.3. Scenario 3
11.2.4. Scenario 4
11.3. Concluding Remarks

12. VALUE CHAIN ANALYSIS

12.1. Chapter Overview
12.2. ADC Development Value Chain
12.3. Cost Distribution across the Value Chain
12.3.1. Cost Associated with Antibody Manufacturing
12.3.2. Cost Associated with Payload and Linker Manufacturing
12.3.3. Cost Associated with Conjugation
12.3.4. Cost Associated with Fill / Finish

13. ADC MANUFACTURING: CAPACITY ANALYSIS

13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. ADC Manufacturing: Global Installed Capacity
13.3.1. Analysis by Company Size
13.3.2. Analysis by Location of Headquarters
13.3.3. Analysis by Location of Manufacturing Facilities
13.3.3.1 Analysis by Region
13.3.3.2. Analysis by Country
13.3.4. Analysis by Key Players

14. ADC THERAPEUTICS: MARKET OVERVIEW

14.1. Chapter Overview
14.2. Antibody Drug Conjugates: Therapies Pipeline
14.2.1. Analysis by Status of Development
14.2.2. Analysis by Target Disease Indication
14.2.3. Analysis by Therapeutic Area
14.2.4. Analysis by Line of Treatment
14.2.5. Analysis by Dosing Frequency
14.2.6. Analysis by Type of Therapy
14.2.7. Analysis by Target Antigen
14.2.8. Analysis by Antibody Isotype
14.2.9. Analysis by Payload / Cytotoxin / Warhead
14.2.10. Analysis by Type of Payload
14.2.11. Analysis by Linker
14.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
14.3. Antibody Drug Conjugates: Therapies to Watch
14.4. Concluding Remarks

15. CLINICAL TRIAL ANALYSIS

15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Antibody Drug Conjugates: Clinical Trial Analysis
15.3.1. Analysis by Trial Registration Year
15.3.2. Analysis by Trial Status
15.3.3. Analysis of Enrolled Patient Population by Trial Status
15.3.4. Analysis by Trial Registration Year and Trial Status
15.3.5. Analysis of Enrolled Patient Population by Trial Registration Year
15.3.6. Analysis by Trial Phase
15.3.7. Analysis of Enrolled Patient Population by Trial Phase
15.3.8. Analysis by Type of Sponsor / Collaborator
15.3.9. Analysis by Target Population
15.3.10. Analysis by Study Design
15.3.11. Most Active Industry Players: Analysis by Number of Trials
15.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
15.3.13. Analysis of Clinical Trials by Geography
15.3.14. Analysis of Enrolled Patient Population by Geography

16. LIKELY PARTNER ANALYSIS

16.1. Chapter Overview
16.2. Scoring Criteria and Key Assumptions
16.3. Scope and Methodology

16.4. Potential Strategic Partners based in North America
16.4.1. Most Likely Partners
16.4.2. Likely Partners
16.4.3. Least Likely Partners
16.5. Potential Strategic Partners based in Europe
16.5.1. Most Likely Partners
16.5.2. Likely Partners
16.5.3. Least Likely Partners
16.6. Potential Strategic Partners based in Asia-Pacific and Rest of the World
16.6.1. Most Likely Partners
16.6.2. Likely Partners
16.6.3. Least Likely Partners

17. ADC THERAPEUTICS: DEMAND ANALYSIS

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. ADC Therapeutics: Global Annual Demand
17.3.1. ADC Therapeutics: Annual Commercial Demand
17.3.1.1. Analysis by Target Indication
17.3.1.2. Analysis by Antibody Origin
17.3.1.3. Analysis by Antibody Isotype
17.3.1.4. Analysis by Type of Payload
17.3.1.5. Analysis by Type of Linker
17.3.1.6 Analysis by Key Geographical Regions
17.3.2. ADC Therapeutics: Annual Clinical Demand
17.3.2.1. Analysis by Phase of Development
17.3.2.2. Analysis by Target Indication
17.3.2.3. Analysis by Antibody Origin
17.3.2.4. Analysis by Antibody Isotype
17.3.2.5. Analysis by Type of Payload
17.3.2.6. Analysis by Type of Linker
17.3.2.7. Analysis by Key Geographical Regions

18. REGIONAL CAPABILITY ANALYSIS

18.1. Chapter Overview
18.2. Assumptions and Key Parameters
18.3. ADC Contract Manufacturing Capabilities in North America
18.4. ADC Contract Manufacturing Capabilities in Europe
18.5. ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World

19. ATTRACTIVENESS COMPETETIVENESS MATRIX

19.1. Chapter Overview
19.2. AC Matrix: Overview
19.2.1. Strong Business Segments
19.2.2. Average Business Segments
19.2.3. Weak Business Segments
19.3. AC Matrix: Analytical Methodology
19.4. AC Matrix: Overall ADC Contract Manufacturing Market Scenario
19.4.1. AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
19.4.2. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions

20. ADC CONTRACT MANUFACTURING MARKET

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Global ADC Therapeutics Market, Historical Trends and Forecasted Estimates, till 2035
20.4. Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
20.4.1. Scenario Analysis
20.5. Key Market Segmentations

21. ADC CONTRACT MANUFACTURING MARKET, BY STAGE OF DEVELOPMENT

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035
21.3.1. Phase I: Forecasted Estimates, till 2035
21.3.2. Phase II: Forecasted Estimates, till 2035
21.3.3. Phase III: Forecasted Estimates, till 2035
21.3.4. Commercial: Forecasted Estimates, till 2035
21.4. Data Triangulation and Validation

22. ADC CONTRACT MANUFACTURING MARKET, BY PROCESS COMPONENT

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035
22.3.1. Antibody: Forecasted Estimates, till 2035
22.3.2. HPAPI / Cytotoxic Payload: Forecasted Estimates, till 2035
22.3.3. Conjugation / Linker: Forecasted Estimates, till 2035
22.3.4. Fill / Finish: Forecasted Estimates, till 2035
22.4. Data Triangulation and Validation

23. ADC CONTRACT MANUFACTURING MARKET, BY TARGET INDICATION

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035
23.3.1. Solid Tumors: Forecasted Estimates, till 2035
23.3.2. Hematological Tumors: Forecasted Estimates, till 2035
23.3.3. Others: Forecasted Estimates, till 2035
23.4. Data Triangulation and Validation

24. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY GENERATION

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035
24.3.1. Second Generation: Forecasted Estimates, till 2035
24.3.2. Third Generation: Forecasted Estimates, till 2035
24.3.3. Fourth Generation: Forecasted Estimates, till 2035
24.3.4. Next Generation: Forecasted Estimates, till 2035
24.4. Data Triangulation and Validation

25. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ORIGIN

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035
25.3.1. Human Origin: Forecasted Estimates, till 2035
25.3.2. Chimeric Origin: Forecasted Estimates, till 2035
25.3.3. Murine Origin: Forecasted Estimates, till 2035
25.3.4. Others: Forecasted Estimates, till 2035
25.4. Data Triangulation and Validation

26. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ISOTYPE

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2029 and 2035
26.3.1. IgG1: Forecasted Estimates, till 2035
26.3.2. IgG4: Forecasted Estimates, till 2035
26.3.3. Others: Forecasted Estimates, till 2035
26.4. Data Triangulation and Validation

27. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF PAYLOAD

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2029 and 2035
27.3.1.Camptothecin: Forecasted Estimates, till 2035
27.3.2. Maytansinoid: Forecasted Estimates, till 2035
27.3.3. Auristatin: Forecasted Estimates, till 2035
27.3.4. DNA topoisomerase I inhibitor: Forecasted Estimates, till 2035
27.3.5. Others: Forecasted Estimates, till 2035
27.4. Data Triangulation and Validation

28. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF LINKER

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2029 and 2035
28.3.1. Maleimide: Forecasted Estimates, till 2035
28.3.2. SMCC: Forecasted Estimates, till 2035
28.3.3. Tetrapeptide-based linker: Forecasted Estimates, till 2035
28.3.4. Valine-citrulline: Forecasted Estimates, till 2035
28.3.5. Others: Forecasted Estimates, till 2035
28.4. Data Triangulation and Validation

29. ADC CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2029 and 2035
29.3.1. North America: Forecasted Estimates, till 2035
29.3.2. Europe: Forecasted Estimates, till 2035
29.3.3. Asia-Pacific and Rest of the World: Forecasted Estimates, till 2035
29.4. Data Triangulation and Validation

30. COMMERCIAL ADC CONTRACT MANUFACTURING MARKET

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
30.3.1. Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
30.3.2. Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
30.3.3. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035
30.3.4. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
30.3.5. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
30.3.6. Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
30.3.7. Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
30.3.8. Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035
30.4. Data Triangulation and Validation

31. CLINICAL ADC CONTRACT MANUFACTURING MARKET

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
31.3.1. Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035
31.3.2. Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
31.3.3. Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
31.3.4. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
31.3.5. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
31.3.6. Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
31.3.7. Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
31.3.8. Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035
31.4. Data Triangulation and Validation

32. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

32.1. Chapter Overview
32.2. Market Drivers
32.3. Market Restraints
32.4. Market Opportunities
32.5. Market Challenges
32.6. Conclusion

33. CONCLUDING REMARKS

34. INTERVIEW TRANSCRIPTS

34.1. Chapter Overview
34.2. Company A
34.2.1. Company Snapshot
34.2.2. Interview Transcript: Chief Executive Officer and Technical Business Development Manager
34.3. Company B
34.3.1. Company Snapshot
34.3.2. Interview Transcript: Chief Executive Officer and Founder
34.4. Company C
34.4.1. Company Snapshot
34.4.2. Interview Transcript: Former Chief Executive Officer
34.5. Company D
34.5.1. Company Snapshot
34.5.2. Interview Transcript: Chief Executive Officer and Co-Founder
34.6. Company E
34.6.1. Company Snapshot
34.6.2. Interview Transcript: Chief Commercial Officer
34.7. Company F
34.7.1. Company Snapshot
34.7.2. Interview Transcript: Chief Business Officer
34.8. Company G
34.8.1. Company Snapshot
34.8.2. Interview Transcript: Executive Director and Chief Innovation Officer
34.9. Company H
34.9.1. Company Snapshot
34.9.2. Interview Transcript: Director, Business Development
34.10. Company I
34.10.1. Company Snapshot
34.10.2. Interview Transcript: Former Director of CDMO
34.11. Company J
34.11.1. Company Snapshot
34.11.2. Interview Transcript: Director Corporate Development
34.12. Company K
34.12.1. Company Snapshot
34.12.2. Interview Transcript: Business Development Manager
34.13. Company L
34.13.1. Company Snapshot
34.13.2. Interview Transcript: Director, Business Development and Former Group Product Manager
34.14. Company M
34.14.1. Company Snapshot
34.14.2. Interview Transcript: Former Head of Bioconjugates Commercial Development
34.15. Company N
34.15.1. Company Snapshot
34.15.2. Interview Transcript: Former Site Head
34.16. Company O
34.16.1. Company Snapshot
34.16.2. Interview Transcript: Associate General Manager
34.17. Interview Transcript: Director, Business Development, Leading CMO
34.18. Interview Transcript: Chief Executive Officer, Leading CMO

35. APPENDIX I: TABULATED DATA36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Recent Expansions
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Capacity Analysis
Figure 4.5 Executive Summary: Clinical Trial Analysis
Figure 4.6 Executive Summary: Demand Analysis
Figure 4.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Key Components of an ADC
Figure 5.2 ADC Manufacturing Steps
Figure 5.3 Key Parameters while Selecting a CMO Partner
Figure 6.1 ADC Contract Manufacturers: Distribution by Year of Establishment
Figure 6.2 ADC Contract Manufacturers: Distribution by Company Size
Figure 6.3 ADC Contract Manufacturers: Distribution by Location of Headquarters(Region)
Figure 6.4 ADC Contract Manufacturers: Distribution by Location of Headquarters(Country)
Figure 6.5 ADC Contract Manufacturers: Distribution by Company Size and Location of Headquarters
Figure 6.6 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
Figure 6.7 ADC Contract Manufacturers: Distribution by Location of Headquartersand ADC Manufacturing Service Offered
Figure 6.8 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
Figure 6.9 ADC Contract Manufacturers: Distribution by Scale of Operation
Figure 6.10 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered and Scale of Operation
Figure 6.11 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
Figure 7.1 Lonza: Annual Revenues, FY 2019-H1 FY 2023 (CHF Billion)
Figure 7.2 WuXi Biologics: Annual Revenues, FY 2019-H1 FY 2023 (RMB Billion)
Figure 7.3 Catalent Pharma Solutions: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
Figure 8.1 Company Competitiveness Analysis: ADC Contract Manufacturers based in North America
Figure 8.2 Company Competitiveness Analysis: ADC Contract Manufacturers based in Europe
Figure 8.3 Company Competitiveness Analysis: ADC Contract Manufacturers based in Asia-Pacific
Figure 8.4 Capability Benchmarking: Distribution of Top 9 Players (Wind Rose Representation)
Figure 9.1 Recent Expansions: Cumulative Year-wise Trend, 2013-2023
Figure 9.2 Recent Expansions: Distribution by Type of Expansion
Figure 9.3 Recent Expansions: Distribution by Purpose of Expansion
Figure 9.4 Recent Expansions: Distribution by Year of Expansion and Purpose of Expansion
Figure 9.5 Recent Expansions: Distribution by Scale of Operation
Figure 9.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 9.7 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Figure 9.8 Most Active Players: Distribution by Number of Expansions
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 10.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.6 Most Active Players: Distribution by Number of Partnership Instances
Figure 10.7 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 10.8 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 11.1 Make versus Buy Decision Making Framework
Figure 11.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 12.1 Value Chain Analysis: ADC Development Overview
Figure 12.2 Value Chain Analysis: ADC Contract Manufacturing Overview
Figure 12.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing
Figure 12.4 Value Chain Analysis: Distribution by Cost
Figure 12.5 Costs Associated with Antibody Manufacturing
Figure 12.6 Costs Associated with Payload and Linker Manufacturing
Figure 12.7 Costs Associated with Conjugation
Figure 12.8 Costs Associated with Fill / Finish
Figure 13.1 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
Figure 13.2 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Figure 13.3 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Region)
Figure 13.4 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country)
Figure 13.5 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
Figure 14.1 Antibody Drug Conjugates: Distribution by Status of Development
Figure 14.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
Figure 14.3 Antibody Drug Conjugates: Distribution by Therapeutic Area
Figure 14.4 Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 14.5 Antibody Drug Conjugates: Distribution by Dosing Frequency
Figure 14.6 Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 14.7 Antibody Drug Conjugates: Distribution by Target Antigen
Figure 14.8 Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 14.9 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Figure 14.10 Antibody Drug Conjugates: Distribution by Type of Payload
Figure 14.11 Antibody Drug Conjugates: Distribution by Linker
Figure 14.12 Antibody Drug Conjugates: Distribution by Type of Linker
Figure 15.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2016-2023
Figure 15.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 15.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Figure 15.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2023
Figure 15.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2016-2023
Figure 15.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 15.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 15.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 15.9 Clinical Trial Analysis: Distribution by Target Population
Figure 15.10 Clinical Trial Analysis: Distribution by Study Design
Figure 15.11 Most Active Industry Players: Distribution by Number of Trials
Figure 15.12 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 15.13 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 15.14 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 17.1 Global Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.2 Global Demand for ADC Therapeutics: Distribution by Stage of Development, 2023-2035 (in kg)
Figure 17.3 Global Commercial Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.4 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Figure 17.5 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2023-2035 (in kg)
Figure 17.6 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Figure 17.7 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Figure 17.8 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Figure 17.9 Global Commercial Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Figure 17.10 Global Clinical Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.11 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2023-2035 (in kg)
Figure 17.12 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Figure 17.13 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Figure 17.14 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Figure 17.15 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Figure 17.16 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Figure 17.17 Global Clinical Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Figure 18.1 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in North America
Figure 18.2 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Europe
Figure 18.3 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
Figure 19.1 AC Matrix: Pictorial Representation
Figure 19.2 AC Matrix: Overall ADC Contract Manufacturing Market Scenario, 2023-2028 and 2029-2035
Figure 19.3 AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
Figure 19.4 AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions
Figure 20.1 Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
Figure 20.2 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Base Scenario (USD Million)
Figure 20.3 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Million)
Figure 20.4 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Million)
Figure 21.1 Global ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035 (USD Million)
Figure 21.2 ADC Contract Manufacturing Market for Phase I ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.3 ADC Contract Manufacturing Market for Phase II ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.4 ADC Contract Manufacturing Market for Phase III ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.5 ADC Contract Manufacturing Market for Commercial ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 22.1 Global ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035 (USD Million)
Figure 22.2 ADC Contract Manufacturing Market for Antibody, Forecasted Estimates, till 2035 (USD Million)
Figure 22.3 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 22.4 ADC Contract Manufacturing Market for Conjugation / Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 22.5 ADC Contract Manufacturing Market for Fill / Finish, Forecasted Estimates, till 2035 (USD Million)
Figure 23.1 Global ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035 (USD Million)
Figure 23.2 ADC Contract Manufacturing Market for Solid Tumors, Forecasted Estimates, till 2035 (USD Million)
Figure 23.3 ADC Contract Manufacturing Market for Hematological Tumors, Forecasted Estimates, till 2035 (USD Million)
Figure 23.4 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 24.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035 (USD Million)
Figure 24.2 ADC Contract Manufacturing Market for Second Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.3 ADC Contract Manufacturing Market for Third Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.4 ADC Contract Manufacturing Market for Fourth Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.5 ADC Contract Manufacturing Market for Next Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 25.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035 (USD Million)
Figure 25.2 ADC Contract Manufacturing Market for Humanized Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.3 ADC Contract Manufacturing Market for Chimeric Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.4 ADC Contract Manufacturing Market for Murine Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.5 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 26.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2028 and 2035 (USD Million)
Figure 26.2 ADC Contract Manufacturing Market for IgG1, Forecasted Estimates, till 2035 (USD Million)
Figure 26.3 ADC Contract Manufacturing Market for IgG4, Forecasted Estimates, till 2035 (USD Million)
Figure 26.4 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 27.1 Global ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2028 and 2035 (USD Million)
Figure 27.2 ADC Contract Manufacturing Market for Camptothecin, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.3 ADC Contract Manufacturing Market for Maytansinoid, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.4 ADC Contract Manufacturing Market for Auristatin, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.5 ADC Contract Manufacturing Market for DNA Topoisomerase I Inhibitor, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.6 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 28.1 Global ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2028 and 2035 (USD Million)
Figure 28.2 ADC Contract Manufacturing Market for Maleimide, Forecasted Estimates, till 2035 (USD Million)
Figure 28.3 ADC Contract Manufacturing Market for SMCC, Forecasted Estimates, till 2035 (USD Million)
Figure 28.4 ADC Contract Manufacturing Market for Tetrapeptide-based linker, Forecasted Estimates, till 2035 (USD Million)
Figure 28.5 ADC Contract Manufacturing Market for Valine-citrulline, Forecasted Estimates, till 2035 (USD Million)
Figure 28.6 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 29.1 Global ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
Figure 29.2 ADC Contract Manufacturing Market in North America, Forecasted Estimates, till 2035 (USD Million)
Figure 29.3 ADC Contract Manufacturing Market in Europe, Forecasted Estimates, till 2035 (USD Million)
Figure 29.4 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Forecasted Estimates, till 2035 (USD Million)
Figure 30.1 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Figure 30.2 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Figure 30.3 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Figure 30.4 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 30.5 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 30.6 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Figure 30.7 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 30.8 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 30.9 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Figure 31.1 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Figure 31.2 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Million)
Figure 31.3 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Figure 31.4 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Figure 31.5 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 31.6 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Figure 31.7 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 31.8 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 31.9 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Figure 33.1 Concluding Remarks: Market Landscape
Figure 33.2 Concluding Remarks: Recent Expansions
Figure 33.3 Concluding Remarks: Partnerships and Collaborations
Figure 33.4 Concluding Remarks: Clinical Trial Analysis
Figure 33.5 Concluding Remarks: Likely Partner Analysis
Figure 33.6 Concluding Remarks: Capacity Analysis
Figure 33.7 Concluding Remarks: Demand Analysis
Figure 33.8 Concluding Remarks: Market Sizing and Opportunity Analysis (1/3)
Figure 33.9 Concluding Remarks: Market Sizing and Opportunity Analysis (2/3)
Figure 33.10 Concluding Remarks: Market Sizing and Opportunity Analysis (3/3)

LIST OF TABLES

Table 5.1 Common Cytotoxins used for the Production od ADCs
Table 5.2 Safebridge Categorization / OEL Bands for Highly Potent / Cytotoxic Compounds
Table 6.1 ADC Contract Manufacturers: Information on Year of Establishment, Company Size, Location of Headquarters and Type of Manufacturer
Table 6.2 ADC Contract Manufacturers: Information on Type of ADC Manufacturing Service Offered
Table 6.3 ADC Contract Manufacturers: Information on Type of Additional Service Offered and Scale of Operation
Table 6.4 ADC Contract Manufacturers: Information on Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
Table 7.1 List of Companies Profiled
Table 7.2 MabPlex: Company Overview
Table 7.3 MabPlex: ADC Related Services
Table 7.4 MabPlex: Information on Manufacturing Facilities
Table 7.5 Lonza: Company Overview
Table 7.6 Lonza: ADC Related Services
Table 7.7 Lonza: Information on Manufacturing Facilities
Table 7.8 Lonza: Recent Developments and Future Outlook
Table 7.9 Abzena: Company Overview
Table 7.10 Abzena: ADC Related Services
Table 7.11 Abzena: Information on Manufacturing Facilities
Table 7.12 Abzena: Recent Developments and Future Outlook
Table 7.13 GBI: Company Overview
Table 7.14 GBI: ADC Related Services
Table 7.15 GBI: Information on Manufacturing Facilities
Table 7.16 CARBOGEN AMCIS: Company Overview
Table 7.17 CARBOGEN AMCIS: ADC Related Services
Table 7.18 CARBOGEN AMCIS: Information on Manufacturing Facilities
Table 7.19 CARBOGEN AMCIS: Recent Developments and Future Outlook
Table 7.20 Millipore Sigma: Company Overview
Table 7.21 Millipore Sigma: ADC Related Services
Table 7.22 Millipore Sigma: Information on Manufacturing Facilities
Table 7.23 WuXi Biologics: Company Overview
Table 7.24 WuXi Biologics: ADC Related Services
Table 7.25 WuXi Biologics: Information on Manufacturing Facilities
Table 7.26 WuXi Biologics: Recent Developments and Future Outlook
Table 7.27 Catalent Pharma Solutions: Company Overview
Table 7.28 Catalent Pharma Solutions: ADC Related Services
Table 7.29 Catalent Pharma Solutions: Information on Manufacturing Facilities
Table 7.30 Catalent Pharma Solutions: Recent Developments and Future Outlook
Table 7.31 Cerbios-Pharma: Company Overview
Table 7.32 Cerbios-Pharma: ADC Related Services
Table 7.33 Cerbios-Pharma: Information on Manufacturing Facilities
Table 7.34 Cerbios-Pharma: Recent Developments and Future Outlook
Table 7.35 Formosa Laboratories: Company Overview
Table 7.36 Formosa Laboratories: ADC Related Services
Table 7.37 Formosa Laboratories: Information on Manufacturing Facilities
Table 7.38 Sterling Pharma Solutions: Company Overview
Table 7.39 Sterling Pharma Solutions: ADC Related Services
Table 7.40 Sterling Pharma Solutions: Information on Manufacturing Facilities
Table 7.41 Sterling Pharma Solutions: Recent Developments and Future Outlook
Table 7.42 Piramal Pharma Solutions: Company Overview
Table 7.43 Piramal Pharma Solutions: ADC Related Services
Table 7.44 Piramal Pharma Solutions: Information on Manufacturing Facilities
Table 7.45 Piramal Pharma Solutions: Recent Developments and Future Outlook
Table 7.46 AbbVie Contract Manufacturing: Company Overview
Table 7.47 AbbVie Contract Manufacturing: ADC Related Services
Table 7.48 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
Table 9.1 ADC Contract Manufacturers: Information on Month and Year of Expansion, Type of Expansion, Purpose of Expansion and Scale of Operation, 2019-2023
Table 9.2 ADC Contract Manufacturers: Information on Location of Expanded Facility and Type of Facility
Table 10.1 ADC Contract Manufacturers: Information on Year of Partnership, Type of Partnership, Purpose of Partnership and Scale of Operation, 2019-2023
Table 10.2 ADC Contract Manufacturers: Information on Type of Agreement (Country and Continent)
Table 12.1 ADC Components: Information on Cost of Cytotoxins
Table 12.2 ADC Components: Information on Cost of Linkers
Table 13.1 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Yield)
Table 13.2 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Average Capacity)
Table 13.3 Global Installed ADC Manufacturing Capacity: Information on Total Capacity based on CompanySize
Table 14.1 Antibody Drug Conjugates: Information on Drug Candidates, Developers, Status of Development,Target Disease Indication and Therapeutic Area
Table 14.2 Antibody Drug Conjugates to Watch: Information on Drug Candidates, Developer, Status of Development, Target Disease Indication and Therapeutic Area
Table 16.1 Most Likely Partners based in North America
Table 16.2 Likely Partners based in North America
Table 16.3 Least Likely Partners based in North America
Table 16.4 Most Likely Partners based in Europe
Table 16.5 Likely Partners based in Europe
Table 16.6 Least Likely Partners based in Europe
Table 16.7 Most Likely Partners based in Asia-Pacific and Rest of the World
Table 16.8 Likely Partners based in Asia-Pacific and Rest of the World
Table 16.9 Least Likely Partners based in Asia-Pacific and Rest of the World
Table 17.1 List of Late Stage ADCs
Table 34.1 BSP Pharmaceuticals: Key Highlights
Table 34.2 Oxford BioTherapeutics: Key Highlights
Table 34.3 Abzena: Key Highlights
Table 34.4 Syndivia: Key Highlights
Table 34.5 Cerbios-Pharma: Key Highlights
Table 34.6 NBE-Therapeutics: Key Highlights
Table 34.7 Eisai: Key Highlights
Table 34.8 Synaffix: Key Highlights
Table 34.9 Pierre Fabre: Key Highlights
Table 34.10 Goodwin Biotechnology: Key Highlights
Table 34.11 Cerbios-Pharma: Key Highlights
Table 34.12 Catalent Pharma Solutions: Key Highlights
Table 34.13 Lonza: Key Highlights
Table 34.14 Piramal Pharma Solutions: Key Highlights
Table 34.15 Ajinomoto Bio-Pharma Services: Key Highlights
Table 35.1 ADC Contract Manufacturers: Distribution by Year of Establishment
Table 35.2 ADC Contract Manufacturers: Distribution by Company Size
Table 35.3 ADC Contract Manufacturers: Distribution by Location of Headquarters (Region)
Table 35.4 ADC Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 35.5 ADC Contract Manufacturers: Distribution by Company Size and Location of Headquarters
Table 35.6 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
Table 35.7 ADC Contract Manufacturers: Distribution by Location of Headquarters and ADC Manufacturing Service Offered
Table 35.8 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
Table 35.9 ADC Contract Manufacturers: Distribution by Scale of Operation
Table 35.10 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered and Scale of Operation
Table 35.11 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
Table 35.12 Lonza: Annual Revenues, FY 2019-H1 FY 2023 (CHF Billion)
Table 35.13 WuXi Biologics: Annual Revenues, FY 2019-H1 FY 2023 (RMB Billion)
Table 35.14 Catalent Pharma Solutions: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
Table 35.15 Recent Expansions: Cumulative Year-wise Trend, 2013-2023
Table 35.16 Recent Expansions: Distribution by Type of Expansion
Table 35.17 Recent Expansions: Distribution by Purpose of Expansion
Table 35.18 Recent Expansions: Distribution by Year of Expansion and Purpose of Expansion
Table 35.19 Recent Expansions: Distribution by Scale of Operation
Table 35.20 Recent Expansions: Distribution by Location of Expanded Facility
Table 35.21 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Table 35.22 Most Active Players: Distribution by Number of Expansions
Table 35.23 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2023
Table 35.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 35.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 35.26 Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 35.27 Partnerships and Collaborations: Distribution by Scale of Operation
Table 35.28 Most Active Players: Distribution by Number of Partnership Instances
Table 35.29 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 35.30 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 35.31 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
Table 35.32 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Table 35.33 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Region)
Table 35.34 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country)
Table 35.35 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
Table 35.36 Antibody Drug Conjugates: Distribution by Status of Development
Table 35.37 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 35.38 Antibody Drug Conjugates: Distribution by Therapeutic Area
Table 35.39 Antibody Drug Conjugates: Distribution by Line of Treatment
Table 35.40 Antibody Drug Conjugates: Distribution by Dosing Frequency
Table 35.41 Antibody Drug Conjugates: Distribution by Type of Therapy
Table 35.42 Antibody Drug Conjugates: Distribution by Target Antigen
Table 35.43 Antibody Drug Conjugates: Distribution by Antibody Isotype
Table 35.44 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Table 35.45 Antibody Drug Conjugates: Distribution by Type of Payload
Table 35.46 Antibody Drug Conjugates: Distribution by Linker
Table 35.47 Antibody Drug Conjugates: Distribution by Type of Linker
Table 35.48 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2016-2023
Table 35.49 Clinical Trial Analysis: Distribution by Trial Status
Table 35.50 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Table 35.51 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2023
Table 35.52 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2016-2023
Table 35.53 Clinical Trial Analysis: Distribution by Trial Phase
Table 35.54 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 35.55 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 35.56 Clinical Trial Analysis: Distribution by Target Population
Table 35.57 Clinical Trial Analysis: Distribution by Study Design
Table 35.58 Most Active Industry Players: Distribution by Number of Trials
Table 35.59 Most Active Non-Industry Players: Distribution by Number of Trials
Table 35.60 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 35.61 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 35.62 Global Demand for ADC Therapeutics, 2023-2035 (in kg)
Table 35.63 Global Demand for ADC Therapeutics: Distribution by Stage of Development, 2023-2035 (in kg)
Table 35.64 Global Commercial Demand for ADC Therapeutics, 2023-2035 (in kg)
Table 35.65 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Table 35.66 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2023-2035 (in kg)
Table 35.67 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Table 35.68 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Table 35.69 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Table 35.70 Global Commercial Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Table 35.71 Global Clinical Demand for ADC Therapeutics, 2023-2035 (in kg)
Table 35.72 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2023-2035 (in kg)
Table 35.73 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Table 35.74 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Table 35.75 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Table 35.76 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Table 35.77 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Table 35.78 Global Clinical Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Table 35.79 Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035 (USD Billion)
Table 35.80 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Billion)
Table 35.81 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Billion)
Table 35.82 Global ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035 (USD Billion)
Table 35.83 ADC Contract Manufacturing Market for Phase I ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.84 ADC Contract Manufacturing Market for Phase II ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.85 ADC Contract Manufacturing Market for Phase III ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.86 ADC Contract Manufacturing Market for Commercial ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.87 Global ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035 (USD Billion)
Table 35.88 ADC Contract Manufacturing Market for Antibody, Forecasted Estimates, till 2035 (USD Billion)
Table 35.89 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payload, Forecasted Estimates, till 2035 (USD Billion)
Table 35.90 ADC Contract Manufacturing Market for Conjugation / Linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.91 ADC Contract Manufacturing Market for Fill / Finish, Forecasted Estimates, till 2035 (USD Billion)
Table 35.92 Global ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035 (USD Billion)
Table 35.93 ADC Contract Manufacturing Market for Solid Tumors, Forecasted Estimates, till 2035 (USD Billion)
Table 35.94 ADC Contract Manufacturing Market for Hematological Tumors, Forecasted Estimates, till 2035 (USD Billion)
Table 35.95 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.96 Global ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035 (USD Billion)
Table 35.97 ADC Contract Manufacturing Market for Second Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.98 ADC Contract Manufacturing Market for Third Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.99 ADC Contract Manufacturing Market for Fourth Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.100 ADC Contract Manufacturing Market for Next Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.101 Global ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035 (USD Billion)
Table 35.102 ADC Contract Manufacturing Market for Human Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.103 ADC Contract Manufacturing Market for Chimeric Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.104 ADC Contract Manufacturing Market for Murine Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.105 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.106 Global ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2028 and 2035 (USD Billion)
Table 35.107 ADC Contract Manufacturing Market for IgG1, Forecasted Estimates, till 2035 (USD Billion)
Table 35.108 ADC Contract Manufacturing Market for IgG4, Forecasted Estimates, till 2035 (USD Billion)
Table 35.109 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.110 Global ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2028 and 2035 (USD Billion)
Table 35.111 ADC Contract Manufacturing Market for Camptothecin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.112 ADC Contract Manufacturing Market for Maytansinoid, Forecasted Estimates, till 2035 (USD Billion)
Table 35.113 ADC Contract Manufacturing Market for Auristatin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.114 ADC Contract Manufacturing Market for DNA Topoisomerase I Inhibitor, Forecasted Estimates, till 2035 (USD Billion)
Table 35.115 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.116 Global ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2028 and 2035 (USD Billion)
Table 35.117 ADC Contract Manufacturing Market for Maleimide, Forecasted Estimates, till 2035 (USD Billion)
Table 35.118 ADC Contract Manufacturing Market for SMCC, Forecasted Estimates, till 2035 (USD Billion)
Table 35.119 ADC Contract Manufacturing Market for Tetrapeptide-based linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.120 ADC Contract Manufacturing Market for Valine-citrulline, Forecasted Estimates, till 2035 (USD Billion)
Table 35.121 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.122 Global ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Billion)
Table 35.123 ADC Contract Manufacturing Market in North America, Forecasted Estimates, till 2035 (USD Billion)
Table 35.124 ADC Contract Manufacturing Market in Europe, Forecasted Estimates, till 2035 (USD Billion)
Table 35.125 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Forecasted Estimates, till 2035 (USD Billion)
Table 35.126 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Billion)
Table 35.127 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Billion)
Table 35.128 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Billion)
Table 35.129 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.130 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.131 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Billion)
Table 35.132 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Billion)
Table 35.133 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.134 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Billion)
Table 35.135 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Billion)
Table 35.136 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Billion)
Table 35.137 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Billion)
Table 35.138 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Billion)
Table 35.139 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.140 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Billion)
Table 35.141 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Billion)
Table 35.142 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.143 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

ADC Therapeutics
Astellas Pharma
AstraZeneca
Byondis
Daiichi Sankyo
Genentech
Gilead Sciences
ImmunoGen
Pfizer
RemeGen
Seagen

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4549EUR$4,799USD£3,800GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6634EUR$6,999USD£5,542GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€17060EUR$17,999USD£14,252GBP

Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions

Antibody Drug Conjugate Market: Growth and Trends

Antibody Drug Conjugate Market: Key Insights

Antibody Drug Conjugate Market Overview

ANTIBODY DRUG CONJUGATE MARKET: KEY SEGMENTS

Breast Cancer is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period

Currently, Solid Tumor Holds Maximum Share within the Antibody Drug Conjugate Market

Maleimidocaproyl is the Fastest Growing Segment in the Antibody Conjugate Market During the Forecast Period

Monomethyl auristatin E (MMAE) Payload is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period

Currently, HER-2 (ERBB2) Target Antigen Holds the Maximum Share within the Antibody Drug Conjugate Market

North America Accounts for the Largest Share of the Market

Key Players in the Antibody Drug Conjugates Market

Primary Research Overview

Antibody Drug Conjugate Market: Research Coverage

Key Questions Answered in this Report

Reasons to Buy this Report

Additional Benefits

Table of Contents

Companies Mentioned (Partial List)

Methodology

Antibody Drug Conjugate Market: Growth and Trends

Antibody Drug Conjugate Market: Key Insights

Antibody Drug Conjugate Market Overview

ANTIBODY DRUG CONJUGATE MARKET: KEY SEGMENTS

Breast Cancer is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period

Currently, Solid Tumor Holds Maximum Share within the Antibody Drug Conjugate Market

Maleimidocaproyl is the Fastest Growing Segment in the Antibody Conjugate Market During the Forecast Period

Monomethyl auristatin E (MMAE) Payload is Likely to Dominate the Antibody Drug Conjugate Market During the Forecast Period

Currently, HER-2 (ERBB2) Target Antigen Holds the Maximum Share within the Antibody Drug Conjugate Market

North America Accounts for the Largest Share of the Market

Key Players in the Antibody Drug Conjugates Market

Primary Research Overview

Antibody Drug Conjugate Market: Research Coverage

Key Questions Answered in this Report

Reasons to Buy this Report

Additional Benefits

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Antibody Drug Conjugates Market Report 2025-2035

Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report by Linker (Cleavable, Non-Cleavable), Condition (Myeloma, Lymphoma, Breast Cancer), and Region with Growth Forecasts, 2025-2030

Antibody-Drug Conjugates: Technologies and Global Markets

Antibody Drug Conjugate - Competitive Landscape, 2025

About the Market